BSE Prices delayed by 5 minutes... << Prices as on Apr 25, 2024 - 3:59PM >>   ABB  6410.95 ATS - Market Arrow  [1.07]  ACC  2579.7 ATS - Market Arrow  [0.85]  AMBUJA CEM  637.75 ATS - Market Arrow  [-0.99]  ASIAN PAINTS  2860.05 ATS - Market Arrow  [-0.25]  AXIS BANK  1127.35 ATS - Market Arrow  [5.98]  BAJAJ AUTO  8736.05 ATS - Market Arrow  [0.61]  BANKOFBARODA  268.7 ATS - Market Arrow  [3.67]  BHARTI AIRTE  1334.9 ATS - Market Arrow  [-0.10]  BHEL  271.6 ATS - Market Arrow  [2.90]  BPCL  603.7 ATS - Market Arrow  [1.78]  BRITANIAINDS  4830 ATS - Market Arrow  [0.04]  CIPLA  1405.4 ATS - Market Arrow  [0.47]  COAL INDIA  452.75 ATS - Market Arrow  [2.10]  COLGATEPALMO  2794.9 ATS - Market Arrow  [1.72]  DABUR INDIA  506 ATS - Market Arrow  [-0.65]  DLF  895.55 ATS - Market Arrow  [0.20]  DRREDDYSLAB  6217.15 ATS - Market Arrow  [4.47]  GAIL  208 ATS - Market Arrow  [0.31]  GRASIM INDS  2375 ATS - Market Arrow  [1.55]  HCLTECHNOLOG  1503.65 ATS - Market Arrow  [1.62]  HDFC  2729.95 ATS - Market Arrow  [-0.62]  HDFC BANK  1510.65 ATS - Market Arrow  [-0.02]  HEROMOTOCORP  4500 ATS - Market Arrow  [2.36]  HIND.UNILEV  2231 ATS - Market Arrow  [-1.25]  HINDALCO  646.5 ATS - Market Arrow  [1.60]  ICICI BANK  1113.05 ATS - Market Arrow  [1.48]  IDFC  124.35 ATS - Market Arrow  [0.20]  INDIANHOTELS  577.5 ATS - Market Arrow  [-5.06]  INDUSINDBANK  1495.95 ATS - Market Arrow  [1.44]  INFOSYS  1438.4 ATS - Market Arrow  [0.46]  ITC LTD  437.5 ATS - Market Arrow  [2.02]  JINDALSTLPOW  942.75 ATS - Market Arrow  [0.68]  KOTAK BANK  1643 ATS - Market Arrow  [-10.85]  L&T  3650.65 ATS - Market Arrow  [0.43]  LUPIN  1589.1 ATS - Market Arrow  [0.57]  MAH&MAH  2095.55 ATS - Market Arrow  [1.76]  MARUTI SUZUK  12900 ATS - Market Arrow  [-0.31]  MTNL  37.35 ATS - Market Arrow  [0.03]  NESTLE  2562.7 ATS - Market Arrow  [2.39]  NIIT  107.6 ATS - Market Arrow  [0.14]  NMDC  252.3 ATS - Market Arrow  [1.73]  NTPC  358.3 ATS - Market Arrow  [1.92]  ONGC  282.05 ATS - Market Arrow  [0.97]  PNB  135.85 ATS - Market Arrow  [2.10]  POWER GRID  292.6 ATS - Market Arrow  [0.71]  RIL  2918.4 ATS - Market Arrow  [0.61]  SBI  812.6 ATS - Market Arrow  [5.10]  SESA GOA  380.8 ATS - Market Arrow  [-0.64]  SHIPPINGCORP  232.75 ATS - Market Arrow  [5.10]  SUNPHRMINDS  1520.55 ATS - Market Arrow  [2.30]  TATA CHEM  1114.9 ATS - Market Arrow  [-1.02]  TATA GLOBAL  1105.95 ATS - Market Arrow  [-0.35]  TATA MOTORS  1000.8 ATS - Market Arrow  [0.93]  TATA STEEL  167.6 ATS - Market Arrow  [1.27]  TATAPOWERCOM  431.5 ATS - Market Arrow  [0.74]  TCS  3851.85 ATS - Market Arrow  [0.54]  TECH MAHINDR  1190.1 ATS - Market Arrow  [0.34]  ULTRATECHCEM  9683.6 ATS - Market Arrow  [0.27]  UNITED SPIRI  1191.85 ATS - Market Arrow  [0.88]  WIPRO  461 ATS - Market Arrow  [0.17]  ZEETELEFILMS  142.75 ATS - Market Arrow  [1.89]  

Lupin Ltd.

Auditor Report

NSE: LUPINEQ BSE: 500257ISIN: INE326A01037INDUSTRY: Pharmaceuticals

BSE   Rs 1589.10   Open: 1581.30   Today's Range 1580.00
1600.00
 
NSE
Rs 1594.40
+14.40 (+ 0.90 %)
+9.05 (+ 0.57 %) Prev Close: 1580.05 52 Week Range 680.35
1703.80
You can view full text of the latest Auditor's Report for the company.
Market Cap. (Rs.) 72664.80 Cr. P/BV 5.83 Book Value (Rs.) 273.50
52 Week High/Low (Rs.) 1704/680 FV/ML 2/1 P/E(X) 168.96
Bookclosure 14/07/2023 EPS (Rs.) 9.44 Div Yield (%) 0.25
Year End :2023-03 

Report on the Audit of the Standalone Financial StatementsOpinion

We have audited the standalone financial statements of Lupin Limited (the "Company”) and its employee welfare trust which comprise the standalone balance sheet as at 31 March 2023, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act”) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2023, and its profit and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter

How the matter was addressed in our audit

1. Revenue Recognition:

Refer note 1B (m) of significant accounting policy and note 28 to standalone financial statements

Revenue from the sale of pharmaceutical products is

To obtain sufficient appropriate audit evidence, our

recognized when control over goods is transferred

principal audit procedures, amongst others, include the

to a customer. The actual point in time when revenue

following:

is recognized varies depending on the specific terms and conditions of the sales contracts entered with customers. The Company has many customers operating in various geographies and sales contracts with customers have distinct terms relating to the recognition of revenue, the right of return and price adjustments.

We identified the recognition of revenue from sale of products as a key audit matter considering:

Revenue is a key performance indicator for the Company. Accordingly, there could be pressure to meet the expectations of investors / other stakeholders and/or to meet revenue targets stipulated in performance incentive schemes for a reporting period. We have considered that there is a risk of fraud related to revenue being overstated by recognition in the wrong period or before control has passed during the year and at period end.

- Compared the accounting policies in respect of revenue recognition with applicable accounting standards to test for compliance.

- Tested design, implementation and operating effectiveness of the Company’s internal controls including general IT controls and key IT application controls over recognition of revenue.

- Performed substantive testing of selected samples of revenue transactions recorded during the year.

- For a sample of year-end sales, we verified contractual terms of sales invoices/ contracts, shipping documents and acknowledged delivery receipts for those transactions including management assessment and quantification of any sales reversal for undelivered goods; and

- Tested any unusual non-standard journal entries that impacted revenue recognized during the year.

The key audit matter

How the matter was addressed in our audit

2. Impairment assessment of investments in subsidiaries (New businesses):

Refer note 7 to standalone financial statements

The Company has invested in new businesses through

To obtain sufficient and appropriate audit evidence, our

its wholly owned subsidiaries (i.e Lupin Diagnostics Limited Rs. 1,581.7 millions, Lupin Digital Health Limited Rs. 1,000.0 millions and Lupin Oncology Inc., USA Rs. 1,127.8 millions) aggregating to Rs. 3,709.5

principal audit procedures, amongst others, included the following:

- Evaluated managements assessment of triggers

millions as at 31 March 2023.

for impairments and assessed the appropriateness of valuation modes used by the management for

These Companies are in early stages of operations and consequently projected performance are not based on any historical trends. Investment in such subsidiaries are evaluated for any triggers for impairment as required under Ind AS 36.

impairment testing.

- Tested the design and operating effectiveness of internal controls over impairment assessment including approval of forecasts and valuation models used.

As a result, an impairment assessment was required

to be performed by the Company by comparing

- Assessed the Valuation methodology used and tested

the carrying value of these investments to their

the mathematical accuracy of the impairment models.

recoverable amount or value in use whichever is

- Evaluated key assumptions in the Company's

higher to determine whether an impairment was

valuation models used to determine recoverable

required to be recognised.

amount/value in use including assumptions of

The Company carries out impairment assessment for

projected earnings before interest, growth rate,

each investment by:

discount rates and identified comparable transactions

- Comparing the carrying value of each investment

in consultation with the valuation specialist.

with the net worth of each company based on

- Evaluated key assumptions in the Company's

latest financial statements.

valuation models used to determine recoverable

- Identifying the most appropriate valuation model

amount including assumptions of projected earnings

considering the business model and its stage of

before interest, growth rate and discount rate. We

operations.

also evaluated the forecasts based on historical

- Comparing the performance of the investee

performance wherever relevant.

companies with projections used for valuations and

- Performed sensitivity analysis of key assumptions and

approved business plans.

evaluated past performances where relevant to assess

- Evaluate variables considered in valuation

accuracy of the forecasts made.

model such as future revenue, margins and

- Assessed and validated the appropriateness of

operating expenditure, appropriate discount rate,

the disclosures made in the standalone financial

identification of comparable transaction, etc. and compute recoverable amount or value in use.

statements.

Considering the inherent uncertainty, subjectivity and judgement involved, impairment assessment of investment has been considered as a key audit matter.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the Company's annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management’s and Board of Directors’ Responsibilities for the Standalone Financial Statements

The Company’s Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor’s Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.

• Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we

are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order”) issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A”

a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. (A) As required by Section 143(3) of the Act, we

report that:

a) We have sought and obtained all the

information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors as on 31

March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B”.

(B) With respect to the other matters to be

included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

a) The Company has disclosed the impact of pending litigations as at 31 March 2023 on its financial position in its standalone financial statements - Refer note 36 to the standalone financial statements.

b) The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts -Refer note 52 to the standalone financial statements.

c) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

d) (i) The management has represented that, to

the best of its knowledge and belief, other than as disclosed in the Note 65 to the

standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 65 to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified

in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e) The final dividend paid by the Company during the year, in respect of the same declared for the previous year, is in accordance with Section 123 of the Act to the extent it applies to payment of dividend.

As stated in note 35 to the standalone financial statements, the Board of Directors of the Company has proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with Section 123 of the Act to the extent it applies to declaration of dividend.

f) As proviso to rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable for the Company only with effect from 1 April 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is not applicable.

(C) With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For B S R & Co. LLP

Chartered Accountants Firm's Registration No.:101248W/W-100022

Venkataramanan Vishwanath

Partner

Place: Mumbai Membership No.: 113156

Date: 09 May 2023 ICAI UDIN: 23113156BGYUJD9102

 
STOCKS A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z|Others

Mutual Fund A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others

SEBI Registration No's: NSE / BSE / MCX : INZ000166638. Depository Participant: IN- DP-224-2016.
Compliance Officer :- Name: Ch.V.A. Varaprasad, Mobile No.: 9393136201, E-mail: varaprasad.challa@rlpsec.com
Grievance Cell: rlpsec_grievancecell@yahoo.com , rlpdp_grievancecell@yahoo.com
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
Copyrights @ 2014 © RLP Securities. All Right Reserved Designed, developed and content provided by